Cognition Therapeutics Inc (NASDAQ:CGTX) shares traded 42.91% higher at $0.58 on Wall Street last session.
CGTX stock price is now 73.27% away from the 50-day moving average and 22.41% away from the 200-day moving average. The market capitalization of the company currently stands at $35.89M.
With the price target enhanced from $1 to $1.50, B. Riley Securities Upgraded its rating from Neutral to Buy for Cognition Therapeutics Inc (NASDAQ: CGTX). , while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Ricciardi Lisa, CEO & President bought 38,851 shares of the company’s stock on Jan 31 ’25. The stock was bought for $30,001 at an average price of $0.77. Upon completion of the transaction, the CEO & President now directly owns 38,851 shares in the company, valued at $22533.58. A total of 19.35% of the company’s stock is owned by insiders.
During the past 12 months, Cognition Therapeutics Inc has had a low of $0.22 and a high of $2.54. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.09, and a quick ratio of 2.09. The fifty day moving average price for CGTX is $0.3341 and a two-hundred day moving average price translates $0.472855 for the stock.
The latest earnings results from Cognition Therapeutics Inc (NASDAQ: CGTX) was released for 2025-03-31. The company reported revenue of $13.78 million for the quarter, compared to $14.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.32 percent.
